Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Clinical trial NCT02255097 · COMPLETED
Trial details
- NCT number
- NCT02255097
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-24
- Primary completion
- 2016-04-22
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.